We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
TBC Bristol-Myers Squibb Australia Pty Ltd
Product name
TBC
Accepted date
Mar-2024
Active ingredients
nivolumab
Proposed indication
Indicated for the neoadjuvant treatment of patients with resectable NSCLC.
Application type
C (new indication)
Publication date
Mar-2024